We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
DIASOURCE (A Biovendor Company)

Download Mobile App




Breast Cancer Test Determines Most Effective Treatment

By LabMedica International staff writers
Posted on 14 May 2019
For the clinical management of patients with estrogen receptor (ER)-positive breast cancer, several clinico-pathological and molecular characteristics of the tumor have to be considered for prognosis and treatment decisions.

Over the last two decades several multigene tests have been developed to aid the selection of patients for whom adjuvant chemotherapy might be appropriate based on prognosis. More...
All of these tests predict the likelihood of disease recurrence or progression, and some have shown to predict relative benefit from chemotherapy.

An international team of scientists working with the Queen Mary University of London (London UK) performed a combined analysis of three large clinical trials, including a total of 3,746 women, who received treatments including hormone therapy and chemotherapy. The investigators found that a multigene test called EndoPredict (Myriad Genetics, Cologne, Germany) is able to predict whether chemotherapy will work for an individual patient.

The study results showed that patients with a high EndoPredict test result, indicating a high risk of metastasis, who received chemotherapy in addition to hormonal therapy, had statistically better 10-year outcomes than those who only received hormonal therapy. The study was therefore able to show that EndoPredict is not only a prognostic test, but for the first time was able to demonstrate that EndoPredict also has predictive abilities with regards to chemotherapy.

With the added predictive benefit of EndoPredict demonstrated by this study, use of this test might become more commonly used to determine whether chemotherapy will effectively treat a patient, bringing enormous benefit to women diagnosed with breast cancer.

Ivana Sestak, PhD, a senior lecturer and lead author of the study, said, “Our new results give clinicians good quality data to inform specific treatment recommendations for women. Our data shows that using the EndoPredict test to assess the risk of metastasis can spare women unnecessary chemotherapy if the test results show that a woman is at low risk of recurrence by the test. The study published on April 30, 2019, in the journal Breast Cancer Research and Treatment.

Related Links:
Queen Mary University of London
Myriad Genetics


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.